MedTrace Logo

Clinical Control Study of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer Recurrence

NCT04404491 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2020-05-27

No results posted yet for this study

Summary

Esophageal cancer is still a serious threat to human life and health. China in particular. Relapse and metastasis are important causes of treatment failure. Immunotherapy is a new treatment method, which can be used in combination with chemotherapy to improve the therapeutic effect. However, the role of immunotherapy combined with chemoradiotherapy in concurrent chemoradiotherapy of recurrent esophageal cancer has not been clearly studied. Our team will study it in detail.

The purpose of this study was to compare and analyze the effect of Camrelizumab in concurrent chemoradiotherapy of locally recurrent esophageal cancer.

Conditions

  • Esophageal Malignant Neoplasm, Local Recurrence

Interventions

DRUG

Procedural death 1

200mg,d1,15,29,43,57,I.V

DRUG

Capecitabine

Capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks in total.

RADIATION

Radiotherapy

radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.

DRUG

Placebo

placebo: 200mg,d1,15,29,43,57,I.V

Sponsors & Collaborators

  • The First Affiliated Hospital of Henan University of Science and Technology

    lead OTHER

Principal Investigators

  • Shegan Gao, M.D,Ph.D · The First Affiliated Hospital of Henan University of Science and Technology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2022-12-30
Completion
2023-06-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04404491 on ClinicalTrials.gov